Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
102 studies found for:    "familial hypertrophic cardiomyopathy" OR "Cardiomyopathy, Hypertrophic"
Show Display Options
Rank Status Study
21 Completed Effects of Continous Positive Airway Pressure (CPAP) in Hypertrophic Cardiomyopathy
Conditions: Non-obstructive Hypertrophic Cardiomyopathy;   Obstructive Hypertrophic Cardiomyopathy
Intervention: Device: CPAP
22 Completed Alcohol Septal Ablation in Obstructive Hypertrophic Cardiomyopathy: A Pilot Study
Condition: Hypertrophic Cardiomyopathy
Intervention: Procedure: trans-right ventricular alcohol septal ablation (TRVASA)
23 Unknown  Biventricular Pacing in Hypertrophic Cardiomyopathy
Condition: Hypertrophic Cardiomyopathy
Intervention: Device: Biventricular Pacemaker
24 Unknown  Trimetazidine Therapy in Hypertrophic Cardiomyopathy
Condition: Hypertrophic Cardiomyopathy
Interventions: Drug: Trimetazidine;   Other: Placebo capsule
25 Recruiting New Diagnostic Strategy in Hypertrophic Cardiomyopathy
Condition: Hypertrophic Cardiomyopathy
Intervention: Other: blood sample
26 Completed
Has Results
Effect of Losartan in Patients With Nonobstructive Hypertrophic Cardiomyopathy
Condition: Hypertrophic Cardiomyopathy
Interventions: Drug: losartan;   Drug: placebo
27 Recruiting Predictive Factors and Consequences of Myocardial Fibrosis in Hypertrophic Cardiomyopathy
Condition: Hypertrophic Cardiomyopathy
Intervention:
28 Active, not recruiting Morbidity and Mortality in Patients With Hypertrophic Cardiomyopathy: a CALIBER Study
Condition: Hypertrophic Cardiomyopathy
Intervention: Other: No intervention
29 Unknown  Diastolic Ventricular Interaction and the Effects of Biventricular Pacing in Hypertrophic Cardiomyopathy
Condition: Hypertrophic Cardiomyopathy
Intervention: Device: Cardiac Resynchronisation Therapy
30 Not yet recruiting Efficacy, Safety, and Tolerability of Perhexiline in Subjects With Hypertrophic Cardiomyopathy and Heart Failure
Condition: Hypertrophic Cardiomyopathy
Interventions: Drug: Perhexiline;   Drug: Placebo
31 Completed Identification of Risk Factors for Arrhythmia in Children and Adolescents With Hypertrophic Cardiomyopathy
Condition: Hypertrophic Cardiomyopathy (HCM)
Intervention:
32 Completed A Comparison of Two Treatments: Pacemaker and Percutaneous Transluminal Septal Ablation for Hypertrophic Cardiomyopathy
Condition: Hypertrophic Cardiomyopathy
Interventions: Procedure: pacemaker implantation;   Procedure: percutaneous transluminal septal ablation (PTSA)
33 Active, not recruiting A Biomarker and MRI Study on Troponin Release After Exercise in Hypertrophic Cardiomyopathy
Condition: Hypertrophic Cardiomyopathy
Intervention:
34 Recruiting Hyper-synchronicity in Hypertrophic Cardiomyopathy (HCM) : Description, Mechanism and Origin With a Multi-imaging Approach to Predict Dual Chamber Pacing Response
Conditions: Hypertrophic Cardiomyopathy;   Mechanical Hyper-synchronicity
Interventions: Procedure: Echocardiography (TEE);   Device: Magnetic resonance imaging (MRI) with gadolinium enhancement;   Device: Magnetic resonance imaging (MRI) without gadolinium enhancement;   Procedure: 3D electrocardiographic mapping (ECM)
35 Unknown  CRyo-Ablation to Treat Patients With HOCM.
Condition: HOCM, Hypertrophic Obstructive Cardiomyopathy
Intervention: Procedure: CRyo-Ablation to Treat HOCM.
36 Completed Neurohormonal Parameters in Hypertrophic Cardiomyopathies
Conditions: 1- Primary (Sarcomeric) Hypertrophic Cardiomyopathy;   2- Obstructive Hypertrophic Cardiomyopathy;   3- Non Obstructive Hypertrophic Cardiomyopathy
Intervention: Other: blood sample collection
37 Completed Factors Contributing to Increased Left Ventricle Size in Patients With Abnormally Enlarged Hearts
Conditions: Hypertrophic Cardiomyopathy;   Left Ventricular Hypertrophy
Intervention:
38 Not yet recruiting Evaluating the Effect of Spironolactone on Hypertrophic Cardiomyopathy
Conditions: Hypertrophic Cardiomyopathy;   Fibrosis
Intervention: Drug: Spironolactone
39 Completed Cyclosporine A to Treat Hypertrophic Cardiomyopathy (HCM)
Conditions: Cardiomyopathy, Hypertrophic;   Heart Hypertrophy
Intervention: Drug: Cyclosporine A
40 Withdrawn Use of Magnetic Field Mapping in the Evaluation of Patients With Hypertrophic Heart Disease (Thick Heart Muscle)
Condition: Hypertrophic Cardiomyopathy
Intervention:

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.